Gregory Weaver Buys 5,000 Shares of Altimmune (NASDAQ:ALT) Stock

Altimmune, Inc. (NASDAQ:ALT) CFO Gregory Weaver purchased 5,000 shares of Altimmune stock in a transaction that occurred on Friday, March 6th. The shares were bought at an average price of $3.54 per share, with a total value of $17,700.00. Following the transaction, the chief financial officer owned 28,078 shares in the company, valued at approximately $99,396.12. The trade was a 21.67% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Altimmune Trading Down 0.5%

Shares of Altimmune stock opened at $3.86 on Wednesday. The company has a current ratio of 18.55, a quick ratio of 17.18 and a debt-to-equity ratio of 0.15. Altimmune, Inc. has a twelve month low of $2.90 and a twelve month high of $7.73. The firm has a market capitalization of $502.07 million, a PE ratio of -3.82 and a beta of 0.13. The firm’s 50-day moving average price is $4.49 and its 200 day moving average price is $4.29.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Altimmune had a negative return on equity of 49.35% and a negative net margin of 214,860.98%.The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.00 million. On average, sell-side analysts predict that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. B. Riley Financial dropped their price target on Altimmune from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Friday, March 6th. Barclays began coverage on Altimmune in a report on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 price objective on the stock. William Blair reaffirmed a “market perform” rating on shares of Altimmune in a research note on Thursday, March 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a report on Monday, December 29th. Finally, Wall Street Zen downgraded shares of Altimmune from a “hold” rating to a “sell” rating in a research note on Saturday. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Altimmune presently has a consensus rating of “Hold” and a consensus target price of $16.60.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC increased its stake in Altimmune by 21.7% during the fourth quarter. Virtu Financial LLC now owns 58,477 shares of the company’s stock worth $211,000 after acquiring an additional 10,409 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Altimmune by 32.7% in the 4th quarter. Invesco Ltd. now owns 214,824 shares of the company’s stock valued at $776,000 after purchasing an additional 52,881 shares during the last quarter. Vines Capital Management LLC purchased a new position in shares of Altimmune during the 4th quarter worth $65,000. Virtus Investment Advisers LLC grew its holdings in shares of Altimmune by 217.2% during the 4th quarter. Virtus Investment Advisers LLC now owns 50,482 shares of the company’s stock worth $182,000 after purchasing an additional 34,568 shares during the period. Finally, Quadrature Capital Ltd acquired a new stake in shares of Altimmune during the 4th quarter worth about $36,000. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.